Treatment of chronic myeloid leukemia in 2007;Le traitement de la leucémie myéloïde chronique en 2007

Bulletin du Cancer

Volumn 94, Issue 10, 2007, Pages 863-869

  Labussière, Hélène ^a   Hayette, Sandrine ^b   Tigaud, Isabelle ^b   Michallet, Mauricette ^a   Nicolini, Franck Emmanuel ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

BCR ABL; Chronic myeloid leukemia; Imatinib mesylate; Resistance

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DASATINIB; DASTINIB; IMATINIB; INTERFERON; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; DRUG TOLERANCE; GENE MUTATION; HUMAN; OVERALL SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SURVIVAL RATE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; PIPERAZINES; PYRIMIDINES;

EID: 36248940273     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0473     Document Type: Review

References (36)

1. Bennett JH. Leucocythemia, white cell blood in relation to the physiology and pathology of the lymphatic glandular system. Edimburgh : Sutherland and Knox eds, 1852.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973 ; 243 : 290-3.
3. Savage DG, Goldman JM. Allografting for chronic myeloid leukemia. Curr Opin Hematol 1997 ; 4 : 369-76.
4. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991 ; 114 : 532-8.
5. Turhan AG. Leucémie myéloïde chronique : actualités biologiques et thérapeutiques. Bull Cancer 2005 ; 92 : 75-82.
6. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid in Europe2006 : transplant activity, long-term data and results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006 ; 91 : 513-21.
7. Baccarani M, Saglio G, Goldman J, Hochaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006 ; 108 : 1809-20.
8. O'Brien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 ; 348 : 994-1004.
9. Drucker B, Guilhot F, O'Brien S, Gathmann I, Kantarjian HM, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med 2006 ; 355 : 2408-17.
10. Hensley ML, Ford JM. Imatinib treatment : specific issues related to safety, fertility, and pregnancy. Sem Hematol 2003 ; 40 : 21-3.
11. Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006 ; 24 : 1204-8.
12. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007 ; 109 : 58-60.
13. Kantarjian HM, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004 ; 103 : 2873-8.
14. Roche-Lestienne C, Preudhomme C. [Recent advances about imatinib mesylate resistance]. Hématologie 2007 ; 13 : 43-53.
15. Labussière H, Hayette S, Nicolini FE. Analysis of the molecular determinants of the response of chronic myelogenous leukaemia to tyrosine kinase inhibitors. Curr Pharmacogenomics 2007 ; 5 : 201-13.
16. Melo J, Chuah C. Résistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007 ; 249 : 121-32.
17. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Pocrio A, et al. ABL mutations in late chronic phase chronic myeloid leukaemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival : a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 2005 ; 18 : 4100-9.
18. Nicolini FE, Corm S, Lê Q-H, Sorel N, Hayette S, Bories D, et al. Mutation status of 89 imatinib mesylate resistant chronic myelogenous leukemia patients and clinical outcome. A retrospective analysis from the french intergroup of CML (Fi(φ)-LMC group). Leukemia 2006 ; 20 : 1061-6.
19. Nicolini FE, Corm S, Lê Q-H, Roche-Lestienne C, Preudhomme C. The prognosis impact of BCR-ABL P-loop mutations : worse or not worse? Leukemia 2007 ; 21 : 193-4.
20. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001 ; 293 : 876-80.
21. Mahon F-X, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571 : diverse mechanisms of resistance. Blood 2000 ; 96 : 1070-9.
22. Mahon F-X, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003 ; 101 : 2368-73.
23. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, et al. P. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107) : reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006 ; 108 : 697-704.
24. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard M-A, et al. Trough plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukaemia. Blood 2007 ; 109 : 3496-9.
25. Martin GS. The road to Src. Oncogene 2004 ; 23 : 7910-7.
26. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006 ; 354 : 2531-41.
27. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006 ; 354 : 2542-51.
28. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogeneous leukemia-comparison with historic experience. Cancer 2005 ; 103 : 2099-108.
29. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, et al. Dasatinib induces significant hematologic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukaemia in accelerated phase. Blood 2007 ; 109 : 4143-50.
30. Réa D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukaemia. Leukemia 2006 ; 20 : 400-3.
31. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002 ; 99 : 3547-53.
32. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukaemia. Blood 2005 ; 105 : 2640-53.
33. Cortes J, Rousselot P, Kim D-W, Ritchie E, Hamersclak N, Coutre S, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or - intolerant chronic myeloid leukemia in blast crisis. Blood 2007 ; 109 : 3207-13.
34. Nicolini F, Hayette S, Corm S, Bachy E, Bories D, Tulliez M, et al. Clinical outcome of 27 imatinib-mesylate-resistant chronic myelogenous leukaemia patients harbouring a T315I BCR-ABL mutation. Haematologica 2007 ; 92 : 1238-41.
35. T315I transcript disappearance in an imatinib-resistant CML patient treated with Homoharringtonine : a new therapeutic challenge? Leukemia 2007 ; (In press).
36. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian HM, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007 ; 109 : 396-7.